Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Trump Says Anthropic No Longer Seen as National Security Threat 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SAN DIEGO, Feb. 02, 2016 -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 3:00 p.m. ET on Tuesday, February 9, 2016. An audio webcast and copy of the presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
MEDIA: David Schull Russo Partners, LLC (858) 717-2310 [email protected] INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 [email protected]
